Vical Provides VL-2397 Updates at BIO International Convention
VL-2397 was initially developed by Astellas Pharma Inc. (TOKYO: 4503). In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397.
Full text Vical site:
Astellas partnership is what makes Vical attractive:
See also pipeline, Astellas is involved in two advanced trials phase II and phase III, see link: